- Home
- AOMR vs ENLV Comparison
AOMR vs ENLV Comparison
Compare AOMR & ENLV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AOMR | ENLV |
|---|---|---|
| Founded | 2018 | 2005 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 218.7M | 249.3M |
| IPO Year | 2021 | 1995 |
Fundamental Metrics
Financial Performance| Metric | AOMR | ENLV |
|---|---|---|
| Price | $9.06 | $1.11 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 2 |
| Target Price | $11.25 | ★ $13.00 |
| AVG Volume (30 Days) | 68.0K | ★ 427.3K |
| Earning Date | 02-25-2026 | 11-14-2025 |
| Dividend Yield | ★ 14.04% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.73 | N/A |
| Revenue | ★ $34,705,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $17.06 | N/A |
| P/E Ratio | $12.44 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.36 | $0.66 |
| 52 Week High | $10.88 | $2.10 |
Technical Indicators
Market Signals| Indicator | AOMR | ENLV |
|---|---|---|
| Relative Strength Index (RSI) | 58.49 | 56.35 |
| Support Level | $8.90 | $1.10 |
| Resistance Level | $9.22 | $1.26 |
| Average True Range (ATR) | 0.17 | 0.08 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 80.85 | 42.59 |
Price Performance
Historical ComparisonAbout AOMR Angel Oak Mortgage REIT Inc.
Angel Oak Mortgage REIT Inc is a real estate finance company focused on acquiring and investing in the first lien non-QM loans and other mortgage-related assets in the U.S. mortgage market. Its objective is to generate attractive risk-adjusted returns for its stockholders, through cash distributions and capital appreciation across interest rates and credit cycles.
About ENLV Enlivex Therapeutics Ltd.
Enlivex Therapeutics Ltd is an Israel-based development-stage biopharmaceutical company. It is focused on developing and commercializing an allogeneic drug pipeline for rebalancing immune hyper-responses. The company's Allocetra is an immunotherapy that is being developed to rebalance a life-threatening unbalanced immune system, using the immune system's own natural regulation mechanisms.